Dr Alfredo Addeo (University Hospital of Geneva, Geneva, Switzerland), Prof Nicolas Girard (Institut Curie, Paris, France), Dr Anna Minchom (Institute of Cancer Research, London, UK) and Prof Pascale Tomasini (Aix-Marseille University, Marseille, France) discuss the latest advances in EGFR-mutant non-small cell lung cancer (NSCLC).

The panel reviews newly presented clinical trial data, evolving treatment strategies, mechanisms of resistance, and innovations in drug delivery that can reshape clinical practice.

They discus emerging results from key studies presented at ESMO 2025, including OptiTROP-Lung04, FLAURA, MARIPOSA, PALOMA, and others.

Experts examine efficacy outcomes, safety profiles, CNS activity, and implications for first-line and sequential therapy selection.

They conclude by discussing advancements in drug delivery and future directions.